Genprex regains Nasdaq $1 bid-price compliance

Genprex, Inc. reported that a Nasdaq Hearings Panel has formally determined the company has regained compliance with the Nasdaq Capital Market $1.00 Minimum Bid Price requirement under Listing Rule 5550(a)(2).

Rhea-AI Filing Summary

Genprex, Inc. reported that a Nasdaq Hearings Panel has formally determined the company has regained compliance with the Nasdaq Capital Market $1.00 Minimum Bid Price requirement under Listing Rule 5550(a)(2). This follows the Panel’s earlier decision granting Genprex an exception to work toward compliance.

The company must now maintain a closing bid price at or above $1.00 for every trading day through December 7, 2026, which is the full extent of the Panel’s discretion on this matter. The Panel will retain jurisdiction over Genprex until that date. If the company becomes non-compliant with any other Nasdaq listing rule before December 7, 2026, it will have seven calendar days to present a plan to cure the deficiency, after which the Panel may either permit additional time for compliance or move to delist the company.

8-K Event Classification

2 items: 3.01, 9.01

2 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Minimum Bid Price Requirement: $1.00 per share Panel Jurisdiction End Date: December 7, 2026 Compliance Notification Date: August 4, 2026 +1 more

4 metrics

Minimum Bid Price Requirement $1.00 per share Nasdaq Listing Rule 5550(a)(2) minimum closing bid price

Panel Jurisdiction End Date December 7, 2026 Date until which the Nasdaq Hearings Panel retains jurisdiction

Compliance Notification Date August 4, 2026 Date Genprex was formally notified it regained bid-price compliance

Response Period for New Deficiencies seven calendar days Time allowed to present a plan if another listing rule is breached

Key Terms

Nasdaq Hearings Panel, Minimum Bid Price requirement, Nasdaq Listing Rule 5550(a)(2), continued listing

4 terms

Nasdaq Hearings Panel regulatory

"on July 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

Minimum Bid Price requirement regulatory

"compliance with the $1.00 Minimum Bid Price requirement set forth"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Listing Rule 5550(a)(2) regulatory

"requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

continued listing regulatory

"Notice of Delisting or Failure to Satisfy a Continued Listing Rule"

When a stock receives a "continued listing," it means the exchange has decided the company’s shares will remain tradable on that market after a review or challenge, often because the company met certain requirements or corrective steps. For investors this matters because continued listing preserves liquidity and access to buy or sell the stock—think of it as a store passing an inspection so customers can keep shopping rather than being forced to close.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Genprex (GNPX) disclose about its Nasdaq listing status?

Genprex disclosed it has regained compliance with Nasdaq’s $1.00 Minimum Bid Price rule. A Nasdaq Hearings Panel confirmed compliance but will retain jurisdiction over the company’s listing until December 7, 2026.

What is the minimum bid price requirement affecting Genprex (GNPX)?

Genprex must maintain a closing bid price of at least $1.00 per share. This requirement is set by Nasdaq Listing Rule 5550(a)(2) and applies to every trading day through December 7, 2026.

How long will the Nasdaq Hearings Panel oversee Genprex (GNPX)?

The Nasdaq Hearings Panel will maintain jurisdiction over Genprex’s listing until December 7, 2026. During this period, the Panel monitors compliance with the bid-price rule and any other Nasdaq listing standards.

What happens if Genprex (GNPX) violates another Nasdaq listing rule?

If Genprex becomes non-compliant with any other Nasdaq listing rule before December 7, 2026, it has seven calendar days to explain its plan to cure the deficiency. The Panel may then grant an exception or move to delist the company.

Which specific Nasdaq rule did Genprex (GNPX) regain compliance with?

Genprex regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 Minimum Bid Price requirement for continued listing on the Nasdaq Capital Market, as confirmed by the Nasdaq Hearings Panel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:32 PM Accepted by SEC EDGAR 08/05/2026 - 04:31 PM Learn about SEC filing dates

false 0001595248 0001595248 2026-08-04 2026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

August 4, 2026

Date of report (Date of earliest event reported)

GENPREX, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38244	90-0772347
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)
3300 Bee Cave Road, #650-227, Austin, TX		78746
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (512) 537-7997

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GNPX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on July 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified Genprex, Inc. (the “Company” or “Genprex”) that the Panel had granted the Company’s request to continue the Company’s listing on The Nasdaq Capital Market (“Nasdaq”) and grant an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”).

On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement. The Panel further informed the Company that until December 7, 2026, which represents the full extent of the Panel’s discretion in this matter with respect to the Bid Price Requirement, the Company must maintain a closing bid price at or above $1.00 for each trading day; and the Panel will maintain jurisdiction over the Company until December 7, 2026.  In the event the Company becomes non-compliant with any other Listing Rule between now and December 7, 2026, the Company will be allowed seven calendar days to advise the Panel on its plan to cure the deficiency.  The Panel will, at that time, determine whether to grant the Company an exception to cure the deficiency or delist the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GENPREX, INC.
Date: August 5, 2026	By:	/s/ Ryan M. Confer
		Ryan M. Confer
		President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB